APTEVO THERAPEUTICS INC. (NASDAQ:APVO) Files An 8-K Financial Statements and ExhibitsItem 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Description |
|
99.1 |
Press Release dated August 10, 2017 |
Aptevo Therapeutics Inc. ExhibitEX-99.1 2 apvo-ex991_6.htm EX-99.1 apvo-ex991_6.htm Exhibit 99.1 For Immediate Release APTEVO THERAPEUTICS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS Showcases Differentiating Features of the ADAPTIR™ Protein Therapeutic Platform at Prominent Industry Conferences Signs Collaboration Agreement with Alligator Bioscience Expanding Aptevo’s Portfolio to Include a New Bispecific Antibody Candidate with a Novel Mechanism of Action Targeting 4-1BB,…To view the full exhibit click here
About APTEVO THERAPEUTICS INC. (NASDAQ:APVO)
Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company’s investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company’s marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).